Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Gouder, L. West, S. Montefort (B'Kara, Malta). Can blood investigations be utilised to predict treatment response to omalizumab?. Eur Respir J 2013; 42: Suppl. 57, 741

Member's Comments

No comment yet.

Related content which might interest you: P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Added value of electronic monitoring in the assessment of asthma control? Source: Annual Congress 2013 –Monitoring symptoms and quality of life Year: 2013 How well can we practically apply asthma guidelines? Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 The clinical and genetic factors for predicting the response to inhaled corticosteroids Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 A new clinically relevant method of calculating adherence Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 The control of asthma in real life: Baseline evaluation of a long-term study Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Safety and tolerability of acute dosing of beta-blockers in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016 E-monitoring of asthma therapy to improve compliance in children (E-MATIC) Source: International Congress 2015 – Paediatric asthma and allergy: e-health in management Year: 2015 REG endpoint validation: Do database asthma control measures predict future risk? Source: International Congress 2014 – Management of asthma and other respiratory diseases in primary care Year: 2014 Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 What are common COPD symptoms in a real-life setting? The German DACCORD registry Source: International Congress 2014 – COPD markers Year: 2014 Demographic, clinical and health care resource utilisation characterisation of patients prescribed omalizumab: A retrospective, real world data study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 In whom should regular asthma controller therapy be initiated? Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Dissociation between clinical trial inclusion and exclusion criteria for trials in severe asthma and the reality of the patient population Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014